AnaptysBio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 48.28 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Details
| Name | AnaptysBio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 104 |
| Founded | 2005 |
| Ipo Date | 2017-01-26 |
| Ceo | Daniel Faga |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| Isin | US0327241065 |
| Cusip | 032724106 |
| Cik | 0001370053 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Daniel R. Faga | President, Chief Executive Officer and Director |
| Christopher M. Murphy | Chief Financial Officer |
| Beth Mueller | Senior Vice President of Human Resources |
| Benjamin Stone | Chief Business Officer |
Contact
| Address | 10770 Wateridge Circle, Suite 210, San Diego, California 92121, United States |
| Phone | 858 362 6295 |
| Website | https://www.anaptysbio.com |